Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents - PubMed
5 hours ago
- #Immunosuppressive therapy
- #Hepatitis B reactivation
- #Chemotherapy risk
- Study used Japanese administrative claims data (2008-2022) to quantify hepatitis B virus reactivation (HBVr) incidence in HBV DNA-negative patients on immunosuppressive or chemotherapeutic agents.
- High-risk agents had the highest incidence: 52.3 per 1000 person-years (PY) after anti-CD20 therapy and 46.5 per 1000 PY for other high-risk agents.
- Moderate-risk agents showed significant incidence: 21.0 per 1000 PY after anthracycline derivatives, 12.1 per 1000 PY after tyrosine kinase inhibitors, and 21.0 per 1000 PY after moderate-to-high-dose corticosteroids for ≥4 weeks.
- Low-dose or short-term corticosteroids were associated with HBVr at 12.4 per 1000 PY, and other uncertain-risk agents (e.g., calcineurin inhibitors) had 12.5 per 1000 PY.
- Findings generally align with current guideline risk stratification but highlight measurable HBVr risk in therapies traditionally considered lower risk.